RNA乙酰化修饰:ac4C测序 acRIP-seq
项目简介
acRIP-seq
N4-acetylcytidine (ac4C),N4位乙酰胞嘧啶,是真核原核生物中保守的化学修饰,早期研究认为ac4C主要存在tRNA和18S rRNA上。而近期研究显示,mRNA上也存在大量的ac4C,该修饰在促进蛋白翻译,影响RNA稳定性和可变剪接,调控基因表达发挥重要作用,有望成为表观转录组学的新兴发展方向。
表观生物ac4C免疫共沉淀测序服务(acRIP-seq),全面解析ac4C在转录组的分布及变化,帮助科研人员深入理解RNA乙酰化在生命和疾病中的作用,促进疾病的精准诊断与治疗研究。
项目流程
RNA乙酰化免疫共沉淀 (acetylated RNA Immunoprecipitation,acRIP)基于抗体特异性结合乙酰化修饰的碱基的原理,以RNA免疫共沉淀富集乙酰化修饰片段为基础,然后通过高通量测序,在全转录组范围内研究发生乙酰化的RNA区域,高效获得结果。
送样要求
样本物种:仅限人、大小鼠,其他物种需评估
>300 ug
总RNA质量
>6x10^7
细胞数量
>150 mg
组织质量
分析内容
分析示例
多组学关联分析四象限图(RNA-seq 与acRIP-seq)
差异Peaks火山图
差异GO分析气泡图
IGV峰图
ac4C修饰metagene图
研究路径图
RNA乙酰化ac4C研究路径图
客户文章
1.Zhan YJ, Deng CM, Tang L, et al. NAT10 Increases Lysosomal Acidification to Promote Esophageal Cancer Metastasis via ac4C Acetylation of ATP6V0E1 mRNA. Adv Sci (Weinh). 2025;12(31):e02931.
2.Lei X, Zheng B, Peng Y, et al. Targeting the NAT10/XIST/YAP1 Axis-Mediated Vascular Abnormalization Enhances Immune Checkpoint Blockade in Gastric Cancer. Int J Biol Sci. 2025;21(11):4997-5014. Published 2025 Jul 28.
3.Liu WC, Wei YH, Chen JF, et al. Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon response via MYC/CDK2/DNMT1 pathway. Nat Commun. 2025;16(1):5154. Published 2025 Jun 3.
4.Dai Y, Li Y, Yang X, et al. Silencing the fibronectin gene (FN1) improves NaCl-induced cardiac fibrosis via ferritinophagy-mediated ferroptosis in a nuclear receptor coactivator 4 (NCOA4)-dependent manner. Br J Pharmacol. 2026;183(3):581-597.
5.Wan X, Wang L, Khan MA, et al. NAT10-mediated N4-acetylcytidine modification in KLF9 mRNA promotes adipogenesis. Cell Death Differ. 2025;32(9):1613-1629.
6.Wang L, Chen E, Zhang S, et al. Targeting the ac4C 'Writer' NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells. Cell Death Dis. 2025;16(1):809. Published 2025 Nov 7.
7.Xiao Z, Wei X, Li P, et al. Impact of N-acetyltransferase 10 on macrophage activation and inflammation-induced cardiac dysfunction. Cell Death Dis. 2025;16(1):471. Published 2025 Jul 1.
8.Li H, Wu H, Li S, et al. Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification. iScience. 2025;28(7):112860. Published 2025 Jun 9.
9.Song A, Liu B, Li W, et al. Competitive binding between DDX21 and SIRT7 enhances NAT10-mediated ac4C modification to promote colorectal cancer metastasis and angiogenesis- DDX21 promotes colorectal cancer metastasis. Cell Death Dis. 2025;16(1):353. Published 2025 Apr 29.
10.Yu C, Chen Y, Luo H, et al. NAT10 promotes vascular remodelling via mRNA ac4C acetylation. Eur Heart J. 2025;46(3):288-304.
11.Huang T, Zhang Y, Niu Y, Xiao Y, Ge Y, Gao J. The Cytidine N-Acetyltransferase NAT10 Promotes Thalamus Hemorrhage-Induced Central Poststroke Pain by Stabilizing Fn14 Expression in Thalamic Neurons. Mol Neurobiol. 2025;62(3):3276-3292.
12.Xie H, Zhang K, Yin H, et al. Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis. J Immunother Cancer. 2025;13(2):e010301. Published 2025 Feb 12.
13.Zhang X, Zheng Y, Yang J, et al. Abnormal ac4C modification in metabolic dysfunction associated steatotic liver cells. Sci Rep. 2025;15(1):1013. Published 2025 Jan 6.
14.Li KJ, Hong Y, Yu YZ, et al. NAT10 Promotes Prostate Cancer Growth and Metastasis by Acetylating mRNAs of HMGA1 and KRT8. Adv Sci (Weinh). 2024;11(32):e2310131.
15.Xie R, Cheng L, Huang M, et al. NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer. Cancer Res 2023 Mar 20.[2] Yang Q, Lei X, He J, et al. N4-Acetylcytidine Drives Glycolysis Addiction in Gastric Cancer via NAT10/SEPT9/HIF-1α Positive Feedback Loop. Adv Sci (Weinh). 2023 Aug;10(23):e2300898.
16.Shi J, Yang C, Zhang J, et al. NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation. Circ Res. 2023 Dec 8;133(12):989-1002.
17.Yan Q, Zhou J, Wang Z, et al. NAT10-dependent N4-acetylcytidine modification mediates PAN RNA stability, KSHV reactivation, and IFI16-related inflammasome activation. Nat Commun. 2023 Oct 10;14(1):6327.